Celldex Therapeutics (NASDAQ: CLDX) released its Q4 earnings report on February 26, 2024, at 07:01 AM. The results showed that the company missed estimated earnings by -12.0%, reporting an EPS of $-0.83 compared to an estimate of $-0.74. However, revenue was up $2.52 million from the same period last year.
This news comes after the company’s performance in the previous quarter, where they also missed on EPS by $0.13. Despite this, there was an 8.0% increase in the share price the next day.
Looking back at Celldex Therapeutics’ past earnings performance, we can see a pattern of missing EPS estimates but often surpassing revenue expectations. For example, in Q3 2023, the EPS estimate was -0.68, but the actual EPS was -0.81, while revenue exceeded expectations at $1.52 million compared to an estimate of $580K.
Investors interested in tracking all earnings releases for Celldex Therapeutics can visit their earnings calendar on the Benzinga website.
It is important to note that this article was generated by Benzinga’s automated content engine and reviewed by an editor. Benzinga does not provide investment advice.
In conclusion, while Celldex Therapeutics may have missed earnings estimates in the latest quarter, the company’s revenue growth is a positive sign for investors. As always, it is essential for investors to conduct their own research and analysis before making any investment decisions.
